Curis Announces Eleven Clinical Sites To Participate In Phase 2 Study Of Emavusertib Combined With Zanubrutinib To Treat Leukemia; Dosing Of Five Patients To Be Completed By Month-End July, Data Expected In December

뉴스 본문을 불러오고 있어요.

Curis Announces Eleven Clinical Sites To Participate In Phase 2 Study Of Emavusertib Combined With Zanubrutinib To Treat Leukemia; Dosing Of Five Patients To Be Completed By Month-End July, Data Expected In December | 웨이프 WAPE

Curis Announces Eleven Clinical Sites To Participate In Phase 2 Study Of Emavusertib Combined With Zanubrutinib To Treat Leukemia; Dosing Of Five Patients To Be Completed By Month-End July, Data Expected In December

기사 요약

관련 종목

댓글 —